NCT03447782View on ClinicalTrials.gov

Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions
New Daily Persistent Headache (NDPH)
Interventions
DRUG

Naltrexone HCl (Bulk) Powder

For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder

Trial Locations (1)

02453

Boston Childrens Hospital, Boston

All Listed Sponsors
lead

Boston Children's Hospital

OTHER

NCT03447782 - Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children | Biotech Hunter | Biotech Hunter